Pere Fontova (Fontova P) is a postdoctoral researcher from the University of Burgos who is currently working in a collaboration with the Cancer Cell Biology Research Group at the University of Barcelona.
He obtained a Degree in Biomedical Sciences and a Master Degree in Biomedicine from University of Barcelona, where he learnt many concepts of both basic and clinical science. During those years as student he made an internship at the Biochemistry Group from University of Barcelona, led by Dr Bartrons and Dr Manzano, where he acquired knowledge and practice in molecular biology techniques focused on glucose metabolism in cancer. Afterwards, he obtained his Ph.D. in the Nephrology Group from the University of Barcelona, led by Dr Lloberas and Dr Grinyó. In his Ph.D he learned more clinical concepts, especially related to the field of immunology. Likewise, he delved deeper into new molecular biology techniques, analytical techniques such as mass spectrometer, and pharmacokinetic and pharmacodynamic analysis of immunosuppressants drugs and their molecular mechanisms.
In 2021, he joined the Bioorganics Chemistry Group from the University of Burgos as a postdoctoral researcher and he started a collaboration with the Cancer Cell Biology Research Group (University of Barcelona), where he is involved in studying the cellular and molecular mechanism, as well as their effectiveness in different cancer models, of different anionophore experimental compounds for cancer treatment.
ORCID ID: 0000-0002-1352-3084; Scopus ID: 57191738451
Selected Publications
- TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Is Upregulated in Lymphocytes Stimulated with Concanavalin A. Simon-Molas H, Vallvé-Martínez X, Caldera-Quevedo I, Fontova P, Arnedo-Pac C, Vidal-Alabró A, Castaño E, Navarro-Sabaté À, Lloberas N, Bartrons R, Manzano A. Int J Mol Sci, 2021.
- Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation. Fontova P, Colom H, Rigo-Bonnin R, van Merendonk LN, Vidal-Alabró A, Montero N, Melilli E, Meneghini M, Manonelles A, Cruzado JM, Torras J, Grinyó JM, Bestard O, Lloberas N. Front Pharmacol. 2021
- Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant Recipients. Fontova P, Colom H, Rigo-Bonnin R, Bestard O, Vidal-Alabró A, van Merendonk LN, Cerezo G, Polo C, Montero N, Melilli E, Manonelles A, Meneghini M, Coloma A, Cruzado JM, Torras J, Grinyó JM, Lloberas N. Clin Phamacol Ther. 2021.
- Mycophenolic acid interferes the transcriptional regulation and protein trafficking of maturation surface markers in dendritic cells. Fontova P, Rama I, Llaudó I, Vidal-Alabró A, Cerezo G, Manzano A, Bestard O, Cruzado JM, Torras J, Grinyó JM, Lloberas N. Int Immunopharmacol. 2021.
- Measurement of calcineurin activity in peripheral blood mononuclear cells by ultra-high performance liquid chromatography-tandem mass spectrometry. Renal transplant recipients application (pharmacodynamic monitoring). Fontova P, Rigo-Bonnin R, Vidal-Alabró A, Cerezo G, Bestard O, Cruzado JM, Torras J, Grinyó JM, Lloberas N. Clin Chimica Acta, 2019.
- PI3K-Akt signaling controls PFKFB3 expression during human T-lymphocyte activation. imon-Molas H, Arnedo-Pac C, Fontova P, Vidal-Alabró A, Castaño E, Rodríguez-García A, Navarro-Sabaté À, Lloberas N, Manzano A, Bartrons R. Mol Cell Biochem, 2018.
- TGF-β1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells. Rodríguez-García A, Samsó P, Fontova P, Simon-Molas H, Manzano A, Castaño E, Rosa JL, Martinez-Outshoorn U, Ventura F, Navarro-Sabaté À, Bartrons R. FEBS J, 2017.
